Ayala Pharmaceuticals, Inc. (ADXS)

Ayala Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	4.88	2.41
Cash & Short-Term Investments	4.88	2.41
Cash Growth	102.74%	-
Receivables	-	0.23
Prepaid Expenses	2.14	0.43
Other Current Assets	0.5	0.12
Total Current Assets	7.53	3.19
Property, Plant & Equipment	0.64	2.42
Goodwill	4.5	-
Other Intangible Assets	3.9	-
Long-Term Deferred Charges	-	1.95
Other Long-Term Assets	0.01	0.21
Total Assets	16.58	7.77
Accounts Payable	6.08	4.08
Accrued Expenses	6.34	1.7
Current Portion of Leases	0.17	0.42
Other Current Liabilities	12.44	-
Total Current Liabilities	25.02	6.2
Long-Term Debt	8.14	-
Long-Term Leases	0.01	1.33
Other Long-Term Liabilities	7.83	1.34
Total Liabilities	41	8.87
Common Stock	0.01	0
Additional Paid-In Capital	172.8	148.05
Retained Earnings	-197.23	-149.15
Shareholders' Equity	-24.42	-1.1
Total Liabilities & Equity	16.58	7.77
Total Debt	8.32	1.75
Net Cash (Debt)	-3.43	0.66
Net Cash Per Share	-0.57	0.23
Filing Date Shares Outstanding	42.63	2.9
Total Common Shares Outstanding	11.9	2.9
Working Capital	-17.49	-3.01
Book Value Per Share	-2.05	-0.38
Tangible Book Value	-32.82	-1.1
Tangible Book Value Per Share	-2.76	-0.38
Machinery	0.25	0.52
Leasehold Improvements	1.11	1.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.